Abliva AB

Quick facts

Marketed products

• Midazolam injection

Phase 2 pipeline

• KL1333 · Oncology
  KL1333 is a small molecule that targets the mitochondrial permeability transition pore (mPTP) to induce cell death in cancer cells.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Abliva AB portfolio CI brief
• Abliva AB pipeline updates RSS